A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2016 Planned End Date changed from 1 Sep 2019 to 1 Nov 2020.
- 01 Nov 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2020.